Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma.

Next Previous
Trial Profile

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DHA-paclitaxel (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors American Regent

Most Recent Events

  • 23 Jul 2025 Status changed from completed to discontinued.
  • 16 Mar 2011 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
  • 16 Mar 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top